References
- Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, . Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1–12.
- Deshpande LM, Jones RN, Fritsche TR, Sader HS. Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000–2004). Microb Drug Resist 2006;12:223–30.
- Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009;9:228–36.
- Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010;65:1119–25.
- Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2008;52:570–3.
- Bratu S, Tolaney P, Karumudi U, Quale J, Mooty M, Nichani S, . Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 2005;56:128–32.
- DeRyke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010;54:4503–5.
- US Food and Drug Administration Safety Communication. Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections, 09-01-2010. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm (accessed 6 October 2010).
- Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29:1099–106.
- Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 20th informational supplement. CLSI document M100-S20.Wayne, PA: CLSI; 2010.
- Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818–29.
- Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; update. CLSI document M100-S20, June 2010 update. Wayne, PA: CLSI; 2010.
- Poudyal A, Howden BP, Bell JM, Gao W, Owen RJ, Turnidge JD, . In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother 2008;62:1311–8.
- Lee J, Patel G, Huprikar S, Calfee DP, Jenkins SG. Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection. J Clin Microbiol 2009;47:1611–2.
- Pournaras S, Kristo I, Vrioni G, Ikonomidis A, Poulou A, Petropoulou D, . Characteristics of meropenem heteroresistance in Klebsiella pneumoniae carbapenemase (KPC)-producing clinical isolates of K. pneumoniae. J Clin Microbiol 2010;48:2601–4.
- Weisenberg SA, Morgan DJ, Espinal-Witter R, Larone DH. Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem. Diagn Microbiol Infect Dis 2009;64:233–5.
- Anderson KF, Lonsway DR, Rasheed JK, Biddle J, Jensen B, McDougal LK, . Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol 2007;45:2723–5.
- Woodford N, Dallow JW, Hill RL, Palepou MF, Pike R, Ward ME, . Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory. Int J Antimicrob Agents 2007;24:456–9.